138403-91-5

Upstream product

• 138403-79-9 ethyl (E)-(4aR*,10R*,10aR*)-10-hydroxy-7-methoxy-3,4,4a,9,10,10a-hexahydrophenanthren-2(1H)-ylideneacetate 
• 138403-93-7 (1S,4R)-4,7,7-Trimethyl-3-oxo-2-oxa-bicyclo[2.2.1]heptane-1-carboxylic acid (4bS,8aS,9S)-7-[1-ethoxycarbonyl-meth-(E)-ylidene]-2-methoxy-4b,5,6,7,8,8a,9,10-octahydro-phenanthren-9-yl ester 
• 138403-76-6 (4aR^*,10R^*,10aR^*)-10-Hydroxy-7-methoxy-3,4,4a,9,10,10a-hexahydrophenanthren-2(1H)-one 
• 3966-32-3 (R)-methoxyphenylacetic acid 
• 138458-37-4 ethyl (E)-(4aS,10S,10aS)-10-hydroxy-7-methoxy-3,4,4a,9,10,10a-hexahydrophenanthren-2(1H)-ylideneacetate 

Relevant academic research and scientific papers

Structural Parallels Between the Cardiotonic Steroids and the Erythrophleum Alkaloids - II. Synthesis and Na(1+),K(1+)-ATPase Inhibitory Activity of Novel Erythrophleum Alkaloid Analogues

Erythrophleum alkaloid analogues, which differ in the ester side-chain configuration, in the nature of the 14-axial substituent (H, Me, Et) and in their absolute configuration, have been prepared.A pronounced trend towards increased Na(1+),K(1+)-ATPase inhibitory activity occurs through the H, Me and Et series, with the E side-chain configuration more active than the Z.This trend is largely confined to the analogues with an absolute configuration matching that of the natural alkaloids.A structural parallel between the 14-axial alkyl substituent of the alkaloids and the D-ring of the cardiotonic steroids is proposed.